Introduction The association of total and cardiovascular disease (CVD) mortality with metabolic syndrome (Mets) is controversial. We estimated the predictive value of MetS and its components for total and CVD mortality.
Introduction
The concept of metabolic syndrome (MetS) refers to a clustering of specific cardiovascular disease (CVD) risk factors including dyslipidemia, glucose intolerance, hypertension (HTN) and central obesity [1] , and its underlying pathophysiology is believed to be related to insulin resistance [2] . As a consequence of the obesity epidemic and sedentary life styles [3] , MetS prevalence is rapidly increasing worldwide [4] and is reported to be 32% in Iranian adults [5] compared to 34% in USA [6] .
Many studies report that MetS is a potential risk factor for poor outcomes such as diabetes, CVDs and mortality [7, 8] . The precise cut off of each component of MetS using different definitions has a strong effect on its prevalence and prognostic significance. A review by international diabetes organizations highlighted some main uncertainties regarding several aspects of MetS including its definition, pathogenesis and association with risk of CVD and even doubting its existence [9] . Limited epidemiological studies have compared the impact of different definitions of MetS on mortality, in particular the Joint Interim Statement (JIS) and International Diabetes Federation (IDF) definitions and the utility and clinical value of MetS in the prediction of total and CVD mortality over its individual components remains controversial. Some studies suggest that MetS is associated with higher risk of all cause and CVD mortality [10, 11] while others report no association [12, 13] . A meta-analysis of 37 studies reported a modest relative risk of mortality among adults having MetS [14] .
Therefore we compared the association of MetS with all cause and CVD morality based on the IDF, modified World Health Organization (WHO) and JIS definitions to assess whether MetS predicts mortality beyond its individual components.
Materials and methods

Study population
This study was conducted within the framework of the Tehran Lipid and Glucose study (TLGS) [15] , an ongoing prospective cohort study being performed to determine the risk factors of atherosclerosis among Tehran's urban population and to develop population-based measures to prevent the rising trend of diabetes mellitus and cardiovascular risk factors. The TLGS performed on a representative sample of residents of district No. 13 of Tehran, capital of Iran. District No. 13 is one of the 22 districts of Tehran metropolitan city which it is located in the eastern part of the city and covers the area of about 13 km 2 and is under coverage of Shahid Beheshti University of Medical Sciences and Health Services. Then three medical health centres of overall 20 medical health centres in the district were selected. All members of each family, including those not having risk factors, were invited for baseline measurements and followed every 3 years. Age and sex distributions of the population in the district were representative of the overall population of Tehran at the time of the baseline examination.
The TLGS has two major components: a cross-sectional prevalence study of non-communicable disease and associated risk factors, implemented between March 1999 and December 2001, and a prospective follow-up study. Data collection is ongoing, designed to continue for at least 20 years, at 3-year intervals. Using multistage stratified cluster random sampling technique, a total of 27 340 residents, aged 3-69 years, who were under the coverage of three medical health centres, invited by telephone call, of which 15 010 residents participated in first examination cycle and another 3551 residents were first examined at the second examination cycle. Participants were categorized into the cohort (n = 10 394) and intervention groups (n = 8167), the latter to be educated for implementation of life style modifications. For the current study, among participants aged ≥30 years (n = 9752), we selected those who participated in the follow-up study until 20 March 2009 (n = 8795).
All subjects gave informed consent at the initiation of the study. A total of 9752 individuals aged ≥ 30 years and participated in phase 1 of TLGS, included in the study; of whom those with missing data (803 individuals), history of cardiovascular and ischemic heart disease (605), body mass index (BMI) < 18.5 (107), GFR < 30 [10] and history of cancer [16] were excluded, leaving 7932 subjects for data analysis. Participants were followed until 20 March 2010, and the mean follow-up duration was 8.95 ± 2.33 years. The study was approved by the Institutional Review Board of Shahid Beheshti University.
Definition of terms
MetS was defined based on each of the three definitions, i.e. [1] IDF, JIS [17] and modified WHO definitions [18] , details of which are shown in Table 1 . The presence of CVD was sought by self-administered questionnaire including questions regarding history of MI, ischemic heart disease, CCU admission, angiography, angioplasty, history of CVA or intermittent claudication.
Cardiovascular mortality
CVD mortality includes mortality caused by myocardial infarction, coronary heart disease, stroke, sudden cardiac death, sudden death and unstable angina. CHD includes cases of definite myocardial infarction diagnosed by electrocardiography (ECG) and biomarkers (creatine phosphokinase-MB, lactate dehydrogenase and troponin), probable myocardial infarction (positive ECG findings plus cardiac symptoms or signs and biomarkers showing negative or equivocal results), unstable angina pectoris (new cardiac symptoms or changing symptom patterns and positive ECG findings with normal biomarkers), angiographic-proven CHD and CHD death. CVD is specified as a composite measure of any CHD events, stroke or cerebrovascular death.
Measures
Weight was determined, while subjects were minimally clothed without shoes, using a digital electronic weighing scale (Seca 707; range 0.1-150 kg, Hanover, MD with an accuracy of up to 100 gr) was regularly checked for precision after every 10 measurements. Waist circumferences was measured using standard protocol by a trained individual, at the level of the umbilicus, using an outstretched tape meter and recorded to the nearest 0.1 cm; WC ≥ 95 cm in both men and women was considered as the national cut-off for determining abdominal obesity. BMI was calculated as weight (kg) divided by height in metres squared. A self-administered validated questionnaire was applied to assess tobacco smoking, personal and family history of diseases and current medication usage. Blood samples were drawn between 7:00 and 9:00 a.m. into vacutainer tubes from all study participants, after 12-14 h overnight fasting. All laboratory kits were supplied by Pars Azmon Inc., Iran. Serum total cholesterol and triglycerides (TGs) were measured using enzymatic calorimetric tests with cholesterol esterase and cholesterol oxidase and glycerol phosphate oxidase, respectively. HDL-C was measured after precipitation of the apolipoprotein B-containing lipoproteins with phosphotungistic acid. LDL-C was calculated from serum TC, TGs and HDL-C concentrations expressed in mg/dL using Friedwald formula if TG concentration was lower than 400 mg/dL. Serum glucose concentration was assayed using enzymatic colorimetric method with glucose oxidase technique. Inter-and intra-assay coefficients of variations were 2.2% for serum glucose, 2 and 0.5% for TC and 1.6 and 0.6% for TGs, respectively. Causes of death were coded according to ICD 10th revision. For the oral glucose tolerance test, 82.5-g glucose monohydrate solution (equivalent to 75-g anhydrous glucose) was administered orally to participants and serum glucose was measured 2 h later. Fasting blood sugar (FBS) and 2-h post glucose challenge were measured on the day of blood collection by the enzymatic colorimetric method using glucose oxidase.
Mortality data: Every participant of the TLGS is followed up for any medical event during prior year by telephone call. He/she is asked for any medical conditions by a trained nurse, and if a related event had occurred a trained physician collects complementary data during a home visit. If necessary, she pays a visit to respected hospital and collects data from medical files. In the case of mortality, data are collected from hospital or death certificate by local physician. Collected data are evaluated by an outcome committee consisted of principal investigator, internist, endocrinologist, cardiologist, epidemiologist and physician who collected outcome data; other experts are invited for evaluation of NCD disorders as needed. Specific outcome for every event is assigned according to ICD-10 criteria and AHA classification for cardiovascular events.
Statistical analyses
Descriptive and mortality analyses were carried out separately in men and women. The impact of MetS on Fasting plasma glucose ≥ 100 mg/dL, or specific treatment Systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg or specific treatment Fasting plasma glucose ≥100 mg/dL or treatment mortality was studied using two Cox regression proportional hazard models; age adjusted in the first model and multivariate adjusted for age, smoking, family history of CVD and total cholesterol in the second. All statistical analyses were carried out using SPSS software package version 17.
Results
During 9 years of follow-up, of the 7932 individuals, there were a total of 330 deaths (4.3%, 199 men and 131 women) from any cause of which 153 deaths (1.8%, 97 men and 47 women) were because of CVD. Mean age of the study population was 47.7 ± 12.4 and 46.2 ± 11.3 years in men and women, respectively. The baseline age of subjects who died during follow-up was 64.1 ± 12.3 in men and 61.9 ± 11.1 years in women. Men had higher cardiovascular (p < 0.001) and total mortality (p < 0.001) than women. Table 2 shows the baseline characteristics of dead and living subjects. At baseline the prevalence of MetS was 28.1, 41.7 and 20.8%, based on the IDF, JIS and WHO definitions, respectively.
After adjustment for age, smoking, family history of CVD and total cholesterol intervention, the MetS, based on the WHO definition was associated with twofold (HR 1.93, 95%CI 1.26-2.94, p = 0.002) and higher (HR 2.71, 95%CI 1.44-5.09, p = 0.002) increased risk of CVD mortality in men and women, respectively. JIS-MetS was associated with excess risk of cardiovascular mortality only in women (HR 2.14, 95%CI 1.05-4.40, p = 0.04) ( Table 3) . To consider the value of assessing MetS in patients with pre-existing type 2 diabetes, we run another model (model 3) adding Diabetes drug users as a confounder and WHO definition was lost its predictive significance.
In the fully adjusted model, the risk (HR) of all cause mortality was strongly associated with the presence of MetS based on the WHO definition; (HR 1.66, 95%CI 1.23-2.24, p < 0.001) in men and (HR 2.01, 95%CI 1.39-2.88, p < 0.001) in women (Table 3) . IDF-MetS only in women was associated with excess risk of total mortality even after further adjustments (HR 1.58, 95%CI 1.11-2.25, p = 0.01) ( Table 4) . After further adjustment for diabetic drug users, none of the Mets group were predictive for total mortality.
We also considered a control group without MetS based on three definitions and calculate the incidence mortality rate (1000000 persons/year) in control subjects and three groups of Mets ( Table 5 ). The incidence of CVD mortality was highest in WHO group (13.4) compared with IDF (8.5), JIS (8.14) and control (5.5) groups. The incidence rate of total mortality for WHO (27.1) was highest compared with IDF (17.7), JIS (16.5) and control (12.9) groups.
Of the five individual components, HTN, impaired fasting glucose (IFG) and abdominal obesity (WC > 95) in men, and TG ≥ 150 mg/dL and IFG in women, independently increased the risk of CVD mortality. In men, HTN was most strongly associated with CVD mortality with twofold excess risk for BP ≥ 140/90 (WHO criteria), and 57% excess risk for BP ≥ 130/85 (JIS and IDF criteria?). For CVD mortality, in men FBS ≥ 100 mg/dL (IDF and JIS criteria) was associated with 66% excess risk (HR 1.66, 95%CI 1.08-2.53, p = 0.02); however IFG based on the WHO-MetS definition (FBS ≥ 110 mg/dL) was associated with approximately 84% excess risk in men (HR Table 6 ).
In men, hazard ratio for total mortality increased with IFG and HTN; however higher TG levels were associated with reduced risk (HR 0.71, 95%CI 0.51-1.00, p = 0.05). FBS ≥ 100 mg/dL and BP ≥ 130/85 were independent determinants of total mortality in men, increasing the risk by 68% and 48%, respectively (Table 7) . In women only IFG was independently predictive of total mortality in the fully adjusted model; FBS ≥ 100 mg/dL was associated with 84% excess risk of total mortality in women. Obesity (WHO criteria, BMI ≥ 30 kg/m 2 or WHR > 0.85) was independently associated with increased risk of total mortality with %100 excess risk (HR 2, 95%CI 1.08-3.68, p = 0.03) ( Table 7) . 
Discussion
To the best of our knowledge, this is the first populationbased cohort study conducted in West Asia with high prevalence of MetS, showing that the concept of MetS based on IDF, JIS and WHO definitions cannot predict the incident of CVD or total mortality over and beyond its individual components neither in men nor women. Although, independent of CVD risk factors, subjects of both genders with MetS, based on the WHO definition had an increased risk of CVD and total mortality but after further controlling for diabetes, WHO-MetS lost its significant association with the incident of mortality. IDF-MetS predicted total mortality only in women even after control for DM drug users. JIS-Mets did not predict total or CVD mortality either in men or women.
Controlling for CVD risk factors, the stronger association of WHO-MetS with increased risk of CVD and total mortality, may be because of the based context of each definition. The JIS-MetS and IDF-MetS definitions in particular were developed, based on the increasing prevalence of obesity worldwide and considering WC as a tool to identify individuals at high CVD risk, whereas WHO-MetS, with dysglycemia as an 'obligatory' component, was defined based on the underlying cause of insulin resistance. Therefore, WHO-MetS includes all subjects with dysglycemia, a component known to be a leading cause of CVD and total mortality [19] [20] [21] . On the other hand, WHO-MetS which has higher threshold for high blood pressure, central obesity and fasting plasma glucose gives less weight to these components and on average identifies only individuals with more severe conditions and higher risk for CVD or total mortality. In line with our finding, previous reports showed that lower cut-offs for these components in more recent definitions such as IDF and JIS lead to a higher prevalence and lower predictive risk [22, 23] . Therefore it seems that the increased risk of CVD and all-cause mortality in patients with WHO-MetS can be attributed to the presence of dysglycemia per se rather than to MetS itself as an entity, demonstrating a high overlap between MetS and dysglycemia, but indicates no added predictive value of MetS for CVD risk [24] . In contrast to our findings, numerous studies have shown the increased risk of all-cause and CVD mortality associated with MetS, such as the Kuopio Ischemic Heart Disease Risk Factor Study [10] , NHANES II [25] , a large cohort of French population [26] and some other studies [27] [28] [29] [30] , even though these studies focused mostly on NCEP, WHO and ATP III criteria rather than those of the JIS or IDF definitions. A study on 4205 middle-aged male veterans indicated that MetS doubles the risk of all-cause and CVD mortality; the syndrome was more informative than its individual components for all-cause mortality but could not be assessed for CVD mortality because of multi-collinearity [31] ; results of this study differed from those of ours, possibly because of the study population, who were just middle-aged males veterans which addressed the mortality rate only in males with MetS. A review article of prospective studies from 1998 to 2004 showed that MetS, based on the WHO/NCEP definition, does an 'unremarkable' job of predicting all-cause mortality (RR of 1.2-1.4) and a 'modest job' of predicting CVDs (RR of 1.7-1.9) [7] . In contrast, the San Antonio Heart Study [32] , of 2372 participants, aged 25-64 years, without initial diabetes and CVD, showed that after adjustment for age, gender and ethnic group, neither the modified WHO nor the NCEP definition predicted all-cause mortality, but the latter was however associated with a twofold increase of CVD mortality. Summarizing evidence from the Cardiovascular Heart Study from 1989 to 2004 conducted on 4258 US adults, 65 years free of CVD, suggested limited utility of MetS (ATP III) for predicting total or CVD mortality in older adults, compared with IFG or HTN [11] . In a populationbased cohort in Germany (SHIP) of 3927 participants, no added predictive value of MetS beyond its individual components with respect to mortality risk was observed, participants with visceral obesity and hyperglycemia being susceptible to the highest risk of total and CVD mortality [33] . In the current study, IDF-MetS predicted total mortality only in women. As high waist circumference is the main component of IDF-Mets, it may be considered the main predictor of total mortality in women, although not independent of other components. Some previous studies have reported a gender-dependent association between MetS and mortality. In a Chinese cohort of 1535 subjects, aged 50 years or older, MetS was associated with excess risk of all-cause mortality only in men [34] . A Lithuanian cohort of 2455 subjects, aged 35-64 years, showed an association between MetS (defined by JIS and IDF) and all-cause and CVD mortality in men [23] . In contrast to these studies, an Italian cohort of 1960, subjects aged 65 years showed that women diagnosed with MetS based on the NCEP, NCEP-R, JIS and IDF definitions had higher risk of all-cause mortality, whereas in men, mortality risk was not associated to MetS [35] . The gender-dependent predictive value of MetS for mortality can be because of the fact that men and women are different in regard to body composition, insulin resistance, and energy balance and waist circumferences [35, 36] . The elevated visceral and hepatic adipose tissue reported in men and the lack of a possible protective effect of estrogen and lower adiponectin levels, may result in higher insulin resistance compared to their female counterparts [36] ; these differences may be explained why men develop CVDs at an earlier age. In addition, in women lower mortality rates and therefore, lack of statistical power can alter the predictive value of MetS for mortality in comparison to men [34] .
The differences in findings between the present study and those of others regarding the importance of the MetS as a risk factor for cardiovascular and total mortality might be because of different definition criteria for MetS and study populations with different age and sex, durations of follow-up, the prevalence of lifestyle factors, smoking, alcohol consumption, ethnicity and occurrence of death as an outcome variable.
Among individual components, HTN, IFG and abdominal obesity in men, and high TG levels and IFG (WHO criteria) in women independently predicted CVD mortality. HTN and IFG, directly, and higher TG levels, inversely, were associated with increased risk of total mortality in men. In women, IFG and obesity (BMI ≥ 30 or WHR < 0.85) predicted total mortality as an independent risk factor. BP ≥ 140/90 (WHO-criteria) was associated with approximately, threefold increase in the risk of CVD mortality, whereas BP ≥ 130/85 (JIS and IDF criteria) was associated with a twofold increase in the risk of CVD mortality following adjustment for CVD risk factors. In men, HTN, followed by IFG was the strongest independent predictors for CVD mortality. HTN provides better prediction for CVD mortality than the IFG component. In line with our results, many studies reported associations between HTN and IFG with CVD or all-cause mortality [11, 21, 34, 37] . Some previous studies report an association between central obesity with mortality [38, 39] ; however, we observed an association between central obesity and CVD mortality only in men, whereas in women, obesity (WHO criteria) was independently associated with excess risk of total mortality.
Despite the known predictive value of high serum TG levels for incident CVD, we found that TG was inversely correlated to the risk of total mortality in men, even though the results of a few studies are consistent with our findings [16, 34, 40, 41] . Lower TG levels may result from malnourishment following weight loss, cancer or chronic inflammatory diseases, conditions which highly contribute to mortality especially in developing countries; however we excluded these conditions at baseline.
Coexistence of different causative patterns in mortality may help us reconcile the divergence we observed in the high TG predictability for CVD versus mortality. In the TLGS 153 (50%) of 330 deaths were attributable to the CVD. The remaining cause of death might not possibly be associated with high TG and therefore attenuated the association of high TG to all-cause mortality.
Gender modifies the hazard ratio of each component for mortality, which may be because of the sex specific pattern of CVD risk factors in the TLGS study; it may also be because of lower smoking rates in Iranian women than men and other related dietary, cultural factors and religious beliefs.
Of the study strengths, it is a population-based study with a long follow-up conducted to determine whether MetS based on different definitions can predict CVD or total mortality beyond its individual components. The study population was recruited as a representative sample of the Iranian population and last, despite the relatively large number of variables adjusted in the models and modest number of events, most analysis had sufficient statistical power.
This study has also limitations needed to be mentioned and addressed. First, the modest number of events limited our conducting age stratified analysis and includes educational status, lifestyle and dietary habits as covariates, each of which may affect mortality. Second, the results cannot be generalized to other populations and the populations with history of CVDs as we excluded those with history of CVD or ischemic heart disease to eliminate confounding. Third, no data were available about the treatment modalities conducted during the follow-up period. Fourth, we could not provide any marker for insulin resistance such as HOMA, which is reported to be an important predictive factor for all-cause and total mortality [42, 43] .
Conclusion
The study findings indicate that MetS has a poor clinical value for predictability of mortality in the Iranian population beyond its components. HTN and dysglycemia in men and only dysglycemia and obesity (WHO criteria) in women were the strongest predictors of all-cause mortality. In men, high TG levels were inversely associated with all-cause mortality. For CVD mortality, dysglycemia and HTN in men and high TG levels and IFG (WHO criteria) in women were the most informative predictors.
